Phronetik
Transforming Healthcare with Data Science

Phronetik: Unmasking Genetics to Improve Health

Thursday, October 05, 2023

The ability to reason, question, and seek answers distinguishes humans from other mammals. Throughout history, our inclination for self-education and the pursuit of knowledge has been a source of comfort, growth, and enlightenment. The quest to understand the unknown, driven by curiosity and a desire for answers, has been central to our existence. While the motivations behind this inquisitiveness vary from personal to societal, what truly matters is that this journey towards truth has consistently benefited society as a whole.

It was this very curiosity and the desire to uncover answers to unexplored questions that led to the establishment of Phronetik. The journey began with a simple query: "How and why do certain individuals develop diseases despite lacking genetic predisposition, family history, or adverse lifestyle choices?" Phronetik was founded to seek answers to such questions. The company's name, a fusion of two Greek words, "phronesis" (wisdom) and "kinetic" (to move), reflects its commitment to utilizing technology and innovation to advance healthcare while progressing with wisdom.

Phronetik, a biotechnology company, advances precision medicine by harnessing OMICS data, artificial intelligence, and informatics to enhance diagnosis, treatment, and monitoring. The company also supports translational research, with a particular focus on precision medicine. Over the years, Phronetik has delved into the science of genetic predisposition, followed by epigenetic studies and population health research. Today, its central focus lies in diagnosing and interpreting data to determine diseases.

The ethos of "Never say Never" permeates Phronetik's culture, championed by Tania Martin-Mercado, President & CEO of Phronetik. She initiated the company in 2013, starting from modest beginnings with no external venture capital or significant seed funding. Her unwavering determination has propelled the company to its current standing. When asked about her motivation, she replied, "I have questioned my sanity from time to time. Then I remember why I'm doing this. Through the efforts of the Phronetik team, its university partners, and industry collaborators, we may help a family predict and prevent the onset of disease. We prevent a death. We improve the quality of care at a practice and the quality of life for a patient. We provide answers where there were previously none. I believe in what we are doing wholeheartedly."

Guided by strong leadership and supported by its staff, Phronetik continually refines its offerings and focus, initially starting with clinical trial services and expanding into sequencing and genetic services. The company collaborates with several CAP/CLIA accredited laboratories, offering genomic testing services such as diagnostic testing, predictive genetic tests, pharmacogenomics, and carrier testing. The OMICS data generated is then processed to provide next-generation sequencing services and data analysis. Phronetik also offers professional services, including strategic planning, technology roadmaps, HIPAA risk assessments, and more. Its managed services, SupportDR™, offer IT support tailored for clinical trials, private practices, and healthcare organizations.

Phronetik remains steadfast in its mission to provide sustainable, innovative, transformative, and disruptive technologies and services to support clinical trials, translational research, and patient-driven outcomes. It embraces a holistic approach to translational and clinical research, advocating for informational transparency and compliant data exchange to advance scientific discovery, ensure reproducible studies, and provide clinicians with accurate, accessible data to enhance healthcare delivery. Phronetik attributes its success to its adaptability and flexibility in catering to client needs, offering a diverse range of services to support their initiatives.

Recognized and acclaimed in leading magazines, Phronetik serves a wide spectrum of sectors, including government, life sciences, hospitals, ambulatory/private practices, pharmaceuticals, non-profits, and community-based organizations.

The company values its employees as much as its customers, fostering motivation, innovation, and a genuine passion for their work. Employees, except for those engaged in lab work, have the freedom to work from home, allowing Phronetik to access top talent in data science and biotech, regardless of location. Employee development is highly encouraged, fostering an environment where creativity and thinking outside the box are celebrated.

As the healthcare and biotechnology landscape continues to evolve, Phronetik's journey persists as an opportunity fueled by passion. It entails discovering ways to contribute to healthcare improvement while contributing to scientific knowledge. The company stays attuned to global developments, from new vaccines to innovative human cell structures, that benefit populations and individual patients. Phronetik remains committed to learning from failures and moving forward with increased vigor.

Phronetik's future goals include establishing its own CAP/CLIA accredited biotechnology laboratory and launching an artificial intelligence engine for point-of-care diagnostics. The company envisions growth and adaptability as it continues to navigate the ever-changing science, technology, and healthcare arena.

Phronetik Selected as Member of ARPA-H Investor Catalyst Hub Spoke Network

Thursday, August 29, 2024

Phronetik Joins a Nationwide Network Working to Accelerate Transformative Health Solutions

FLOWER MOUND- PRLog -- Phronetik® announced today that it was selected as a spoke for the Investor Catalyst Hub, a regional hub of ARPANET-H, a nationwide health innovation network launched by the Advanced Research Projects Agency for Health (ARPA-H).



Based in the Greater Boston area and managed by VentureWell, the Investor Catalyst Hub seeks to accelerate the commercialization of groundbreaking and accessible biomedical solutions. It utilizes an innovative hub-and-spoke model designed to reach a wide range of nonprofit organizations and Minority-Serving Institutions, with the ultimate aim of delivering scalable healthcare outcomes for all Americans.



"As Phronetik continues its commitment to inclusive research, data fairness, and equitable initiatives in biotechnology and genomics, joining the ARPA-H Investor Catalyst Hub Spoke Network is a natural alignment with our mission. By accelerating the commercialization of groundbreaking biomedical solutions, we are not only advancing scientific study and precision medicine but also ensuring that these innovations are accessible to all. We are thrilled to be part of this network, as it allows us to further integrate genomics into patient care and support transformative research that benefits diverse populations."

— Dr. Tania M. Martin-Mercado, CEO of Phronetik



Phronetik joins a dynamic nationwide network of organizations aligned to ARPA-H's overarching mission to improve health outcomes through the following research focus areas: health science futures, proactive health, scalable solutions, and resilient systems. Investor Catalyst Hub spokes represent a broad spectrum of expertise, geographic diversity, and community perspectives.



"Our spoke network embodies a rich and representative range of perspectives and expertise," said Mark Marino, Vice President of Growth Strategy and Development for VentureWell and Project Director for the Investor Catalyst Hub. "Our spokes comprise a diverse network that will be instrumental in ensuring that equitable health solutions reach communities across every state and tribal nation."



As an Investor Catalyst Hub spoke, Phronetik gains access to potential funding and flexible

contracting for faster award execution compared to traditional government contracts. Spoke membership also offers opportunities to provide input on ARPA-H challenge areas and priorities, along with access to valuable networking opportunities and a robust resource library.